Cargando…

Antiretroviral (ARV) Therapy in Resource Poor Countries: What do we Need in Real Life?

Significant progresses have been made in the last 5 years towards the ultimate goal to provide universal access to care for all HIV/AIDS patients needing antiretroviral treatment in resource-poor countries. However, many barriers are still to be overcome, including (●) cost of care for the individua...

Descripción completa

Detalles Bibliográficos
Autores principales:	Castelli, Francesco, Pietra, Virginio, Diallo, Ismael, Schumacher, Richard F., Simpore, Jacques
Formato:	Texto
Lenguaje:	English
Publicado:	Bentham Open 2010
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2817878/ https://www.ncbi.nlm.nih.gov/pubmed/20148089 http://dx.doi.org/10.2174/1874613601004020028

Ejemplares similares

Environmental Risk Characterization of an Antiretroviral (ARV) Lamivudine in Ecosystems
por: Omotola, Elizabeth Oyinkansola, et al.
Publicado: (2021)

Monkeypox Outbreaks in Non-Endemic Countries: What Do We Know and What Do We Need?
por: Shamabadi, Ahmad, et al.
Publicado: (2022)

Effects of a Cereal and Soy Dietary Formula on Rehabilitation of Undernourished Children at Ouagadougou, in Burkina Faso
por: Douamba, Zoenabo, et al.
Publicado: (2012)

ARV-based HIV prevention for women – where we are in 2014
por: Mastro, Timothy D, et al.
Publicado: (2014)

COVID-19 pandemic and antiretrovirals (ARV) availability in Nigeria: recommendations to prevent shortages
por: Dada, David Adelekan, et al.
Publicado: (2020)

Projected Uptake of New Antiretroviral (ARV) Medicines in Adults in Low- and Middle-Income Countries: A Forecast Analysis 2015-2025
por: Gupta, Aastha, et al.
Publicado: (2016)

Patent Pooling for Promoting Access to Antiretroviral Drugs (ARVs) – A Strategic Option for India
por: Satyanarayana, Kanikaram, et al.
Publicado: (2010)

Adverse drug reactions to antiretroviral therapy (ARVs): incidence, type and risk factors in Nigeria
por: Eluwa, George I, et al.
Publicado: (2012)

Global reproductive health – Why do we persist in neglecting the undeniable problem of childlessness in resource-poor countries?
por: Ombelet, W, et al.
Publicado: (2017)

New ARV drugs
por: Gulick, Roy
Publicado: (2014)

Young Women with Breast Cancer in Resource-Limited Settings: What We Know and What We Need to Do Better
por: Martinez-Cannon, Bertha Alejandra, et al.
Publicado: (2021)

Trichomoniasis: How do we diagnose in a resource poor setting?
por: Sivaranjini, R., et al.
Publicado: (2013)

Correction: Adverse drug reactions to antiretroviral therapy (ARVs): incidence, type and risk factors in Nigeria
por: Eluwa, George I, et al.
Publicado: (2012)

Antiretroviral drug resistance and viral tropism in HIV-1 CRF06_cpx infected patients failing antiretroviral (ARV) therapy
por: Pauskar, Merit, et al.
Publicado: (2014)

Why do we Need Quality Articles, What are we Going to do With?
por: Mueen Ahmed, KK
Publicado: (2011)

Development of long-acting ARV’s
por: Boffito, Marta
Publicado: (2014)

Trends in Decline of Antiretroviral Resistance among ARV-Experienced Patients in the HIV Outpatient Study: 1999–2008
por: Buchacz, Kate, et al.
Publicado: (2012)

LB5. Safety of In Utero Antiretroviral (ARV) Exposure: Neurologic Outcomes in HIV-Exposed, Uninfected Children
por: Crowell, Claudia S, et al.
Publicado: (2018)

Drugs for malaria elimination: what do we have now and what do we need?
por: Shanks, Dennis
Publicado: (2014)

Evolutionary ecology of Chagas disease; what do we know and what do we need?
por: Flores‐Ferrer, Alheli, et al.
Publicado: (2017)

Veteran homelessness in Australia: What do we know? What has been done? What do we need to do?
por: Wallace, Duncan, et al.
Publicado: (2023)

50 States or 50 Countries: What Did We Miss and What Do We Do Now?
por: Burkle, Frederick M., et al.
Publicado: (2020)

Equitable Allocation of Antiretrovirals in Resource-Constrained Countries
Publicado: (2005)

Pharmaceutical Equivalence of Distributed Generic Antiretroviral (ARV) in Asian Settings: The Cross-Sectional Surveillance Study – PEDA Study
por: Sapsirisavat, Vorapot, et al.
Publicado: (2016)

Antiretroviral (ARV) Drug Resistance and HIV-1 Subtypes among Injecting Drug Users in the Coastal Region of Kenya
por: Ng'ong'a, Gabriel O., et al.
Publicado: (2022)

Modelling the Impact of Antiretroviral Use in Resource-Poor Settings
por: Baggaley, Rebecca F, et al.
Publicado: (2006)

Financial incentives for human resources for health: What do we know? What do we do? The case of Sierra Leone
por: Bertone, Maria Paola
Publicado: (2014)

Cataract surgery – Where are we today and what do we need?
por: Heda, Aarti, et al.
Publicado: (2022)

ARV regimen choice and co-morbidities
por: Peters, Barry
Publicado: (2014)

Cardiac surgery and the coronavirus disease 2019 pandemic: What we know, what we do not know, and what we need to do
por: Bakaeen, Faisal G., et al.
Publicado: (2020)

Third-Line Antiretroviral Therapy: What Do We Do When the Appropriate Formulations Are Not Available?
por: Frigati, Lisa Jane, et al.
Publicado: (2022)

What Do We Need to Do for Better Casualty Support in Disasters?
por: Nekooei Moghadam, M, et al.
Publicado: (2011)

Pathogen Lists Do Not Tell Us What We Need to Do
por: Fedson, David S.
Publicado: (2019)

Clinical and immunological outcomes according to adherence to first-line HAART in a urban and rural cohort of HIV-infected patients in Burkina Faso, West Africa
por: Focà, Emanuele, et al.
Publicado: (2014)

What do we need for \nu counting in DELPHI ?
por: Clara, M P, et al.
Publicado: (1991)

What do we need to understand and optimize the LHC?
por: Bruning, O S
Publicado: (2010)

Biosimilar therapeutics—what do we need to consider?
por: Schellekens, Huub
Publicado: (2009)

What is vitamin A and why do we need it?
por: Gilbert, Clare
Publicado: (2013)

Publication ethics – What do we need to know?
por: Mills, Michael
Publicado: (2019)

Management of T1 Urothelial Carcinoma of the Bladder: What Do We Know and What Do We Need To Know?
por: Gershman, Boris, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_g3hsvaiqsohom98fpq5cbrch2j